AcquisitionsJul 15, 2026, 09:17 AM
GSK Completes $10.6B Acquisition of Nuvalent, Inc.
AI Summary
GSK plc announced the completion of its acquisition of Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on oncology therapies. The acquisition, valued at approximately $10.6 billion, significantly expands GSK's oncology portfolio with three lung cancer assets. Key assets include zidesamtinib (NVL-520) and neladalkib (NVL-655), both under FDA review with Breakthrough Therapy and Orphan Drug Designations, and expected to launch in 2026 with multi-blockbuster potential.
Key Highlights
- GSK completed the acquisition of Nuvalent, Inc.
- Aggregate equity value of the transaction is approximately $10.6 billion (£8.0 billion).
- Net investment by GSK is approximately $9.4 billion (£7.1 billion).
- Acquisition adds three lung cancer assets to GSK's oncology portfolio.
- Zidesamtinib (NVL-520) and neladalkib (NVL-655) are under FDA review.
- Both Zidesamtinib and neladalkib have received FDA Breakthrough Therapy and Orphan Drug Designations.
- These assets are expected to launch in 2026 with multi-blockbuster potential.
- The acquisition also includes NVL-330 in phase I development for HER2-altered NSCLC.
Price Impact
More from GSK